Search results
Eisai sets new revenue target for Alzheimer’s drug Leqembi
BioPharma Dive via Yahoo Finance· 22 hours agoThe annual forecast, which comes as Eisai and Biogen have begun submitting a more convenient form of...
Is Eli Lilly Stock A Buy Or A Sell With Key Alzheimer's Meeting Looming?
Investor's Business Daily· 19 hours agoThe decision effectively pushes back the approval decision, which was expected in the first quarter....
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Medical Device Network via Yahoo Finance· 3 days agoThe approval of several drugs for Alzheimer’s such as Eisai’s Leqembi (lecanemab) and Biogen’s...
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
InvestorPlace via Yahoo Finance· 7 days agoHere’s a question for you: What determines the value of a drug? Is it the number of lives it saves...
15 Most Depressed States in the US
Insider Monkey via Yahoo Finance· 2 days agoIn this article, we will be taking a look at the 15 most depressed states in the US. If you are not interested in learning about the global and regional...
Cramer's Lightning Round: Bank of America is a buy
CNBC· 5 days ago"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript
Guru Focus· 3 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Voyager Therapeutics Inc (VYGR, Financial) announced IND clearance for VY-TAU01, an anti-tau ...
3 S&P 500 Stocks to Rival Nvidia's 2023 Performance in the Second Half of 2024
InvestorPlace· 5 days agoThe extraordinary performance of Nvidia (NASDAQ:NVDA) in 2023 coincided with a seismic generative-AI...
Sanofi pays $80M to add Roche-rivaling Fulcrum drug to phase 3 rare disease pipeline
FierceBiotech· 3 days agoSanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side of the deal, handing Sanofi ex-U.S. rights to a rare disease candidate ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoNEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference
